Abstract: [Problem to be Solved] It is an object of the present invention to provide a preventive or therapeutic composition for a therapy-resistant cancer having therapy-resistant cancer cells. [Solution] A preventive or therapeutic composition for a therapy-resistant cancer having therapy-resistant cancer cells, which is for use in photodynamic therapy, wherein the composition comprises ALAs.

Abstract: An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.

Abstract: An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.

Abstract: An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.

Abstract: The present invention relates to a method for measuring transporter activity of ABC protein that may measure not only small amount of samples with small data fluctuation and good reproducibility, but also many samples simultaneously and concisely; a screening method for substances that interact with ABC protein using said measuring method; and a kit for measuring transporter activity of ABC protein that may advantageously be used for those methods. Pre-incubation may be carried out by adding the insect cellular membrane expressing human P-glycoprotein to the reaction buffer solution including vanadic acid and [3H] ATP. Following this, the test compound may be added for reaction, after which reaction liquid may be added to a glass filter of 96-well type, and by using the suction cleaning method, adsorption amount of [3H] ADP into the membrane-expressing P-glycoprotein may be measured in a single step.

Abstract: RSP (Repository Service Provider) server 7 receives first data and at least first digital signature for the first data from a TC (Trade Chain) server 3. Next, it performs format conversion corresponding to a destination of the first data, for the received first data to generate second data. Then, it sends a TC server 5, which is associated with the destination, at least the second data generated in the format conversion, a format reverse-conversion program, and the first digital signature. In this way, by sending the format reverse-conversion program and the first digital signature for the first data, for which the format conversion is not performed, it becomes possible to confirm in the TC sever 5 that there is no alteration for the first data and etc. Namely, the TC server 5 can obtain the verification of the TC server 3, which is a transmission source.